Market Overview

UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic and Acquisition Growth Outlook

Share:
Related JAZZ
Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent
Why This Trader Is Worried About Jazz Pharmaceuticals

Credit Suisse initiates its coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform rating and a price target of $65.

Credit Suisse comments, "We rate JAZZ Outperform because it offers (1) organic growth of the Xyrem franchise, driven by volume growth, pricing power and what we see as a defensible franchise against generics until at least 2020, based on our work with patent counsel; (2) diversification, accretion and cash flows provided by Erwinaze, the key product obtained in the recently announced EUSA acquisition; and (3) a platform for acquisitions created by JAZZ's low tax rate, focused acquisition strategy and execution capabilities."

JAZZ closed at $43.66 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Apr 2015Deutsche BankMaintainsBuy
Feb 2015BMO CapitalInitiates Coverage onOutperform
Nov 2014CitigroupMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (JAZZ)

Around the Web, We're Loving...